Dödligt virus från Kina orsakar panik (SARS-CoV-2, COVID-19)

We are testing too many vaccinated people who lack covid symptoms
It’s possible for someone to fight off an infection and still test positive, which skews case numbers

PCR-tekniken som används i test för att påvisa virus kan inte skilja på virus med förmåga att infektera celler och virus som oskadliggjorts av immunförsvaret och därför kan man inte använda dessa test för att avgöra om någon är smittsam eller inte. RNA från virus kan ofta påvisas i veckor (ibland månader) efter insjuknandet men innebär inte att man fortfarande är smittsam.

After more than a year of committing scientific fraud to push false “positives” via PCR testing, the CDC has announced it is withdrawing the RT-PCR Diagnostic Panel on December 31st of this year:

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

The use of PCR tests for covid illness diagnosis is a global scientific fraud, since no PCR instrument can produce quantitative results that might indicate a specific viral load. Yet this CDC-approved testing protocol was relied on to fabricate the “casedemic” illusion which pretended that hundreds of millions of people around the world were infected with covid.

CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.

Since no quantified virus isolates of the 2019-nCoV were available for CDC use at the time the test was developed and this study conducted, assays designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA (N gene; GenBank accession: MN908947.2) of known titer (RNA copies/µL) spiked into a diluent consisting of a suspension of human A549 cells and viral transport medium (VTM) to mimic clinical specimen. Samples were extracted using the QIAGEN EZ1 Advanced XL instrument and EZ1 DSP Virus Kit (Cat# 62724) and manually with the QIAGEN DSP Viral RNA Mini Kit (Cat# 61904). Real-Time RT-PCR assays were performed using the Thermo Fisher Scientific TaqPath™ 1-Step RT-qPCR Master Mix, CG (Cat# A15299) on the Applied Biosystems™ 7500 Fast Dx RealTime PCR Instrument according to the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel instructions for use.